Literature DB >> 18662557

Therapeutic radionuclides: biophysical and radiobiologic principles.

Amin I Kassis1.   

Abstract

Although the general radiobiologic principles underlying external beam therapy and radionuclide therapy are the same, there are significant differences in the biophysical and radiobiologic effects between the 2 types of radiation. In addition to the emission of particulate radiation, targeted radionuclide therapy is characterized by (1) extended exposures and, usually, declining dose rates; (2) nonuniformities in the distribution of radioactivity and, thus, absorbed dose; and (3) particles of varying ionization density and, hence, quality. This review explores the special features that distinguish the biologic effects consequent to the traversal of charged particles through mammalian cells. It also highlights what has been learned when these radionuclides and radiotargeting pharmaceuticals are used to treat cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662557      PMCID: PMC2584872          DOI: 10.1053/j.semnuclmed.2008.05.002

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  41 in total

1.  Therapeutic potential of 5-[125I]iodo-2'-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis.

Authors:  Amin I Kassis; Agop M Kirichian; Ketai Wang; Elham Safaie Semnani; S James Adelstein
Journal:  Int J Radiat Biol       Date:  2004 Nov-Dec       Impact factor: 2.694

2.  Inhibitory and stimulatory bystander effects are differentially induced by Iodine-125 and Iodine-123.

Authors:  Hiroko Kishikawa; Ketai Wang; S James Adelstein; Amin I Kassis
Journal:  Radiat Res       Date:  2006-06       Impact factor: 2.841

Review 3.  MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy?

Authors:  George Sgouros; Susan J Knox; Michael C Joiner; William F Morgan; Amin I Kassis
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

4.  Cytotoxicity of [125I]iodoHoechst 33342: contribution of scavengeable effects.

Authors:  M A Walicka; Y Ding; A M Roy; R S Harapanhalli; S J Adelstein; A I Kassis
Journal:  Int J Radiat Biol       Date:  1999-12       Impact factor: 2.694

5.  Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.

Authors:  P C Chinn; J E Leonard; J Rosenberg; N Hanna; D R Anderson
Journal:  Int J Oncol       Date:  1999-11       Impact factor: 5.650

Review 6.  The amazing world of auger electrons.

Authors:  Amin I Kassis
Journal:  Int J Radiat Biol       Date:  2004 Nov-Dec       Impact factor: 2.694

7.  Alpha particles induce the production of interleukin-8 by human cells.

Authors:  P K Narayanan; K E LaRue; E H Goodwin; B E Lehnert
Journal:  Radiat Res       Date:  1999-07       Impact factor: 2.841

8.  Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.

Authors:  Marie Boyd; Susan C Ross; Jennifer Dorrens; Natasha E Fullerton; Ker Wei Tan; Michael R Zalutsky; Robert J Mairs
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

9.  123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.

Authors:  Sven N Reske; Sandra Deisenhofer; Gerhard Glatting; Boris D Zlatopolskiy; Agnieszka Morgenroth; Andreas T J Vogg; Andreas K Buck; Claudia Friesen
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

10.  (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.

Authors:  Danny L Costantini; Conrad Chan; Zhongli Cai; Katherine A Vallis; Raymond M Reilly
Journal:  J Nucl Med       Date:  2007-07-13       Impact factor: 10.057

View more
  57 in total

1.  Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.

Authors:  Wen-Ting K Tsai; Kirstin A Zettlitz; Magnus Dahlbom; Robert E Reiter; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

Review 2.  Aligning physics and physiology: Engineering antibodies for radionuclide delivery.

Authors:  Wen-Ting K Tsai; Anna M Wu
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-15       Impact factor: 1.921

Review 3.  Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.

Authors:  Murthy R Chamarthy; Scott C Williams; Renee M Moadel
Journal:  Yale J Biol Med       Date:  2011-12

Review 4.  [PSMA-targeted radioligand therapy in prostate cancer].

Authors:  M M Heck; M Retz; R Tauber; K Knorr; C Kratochwil; M Eiber
Journal:  Urologe A       Date:  2017-01       Impact factor: 0.639

Review 5.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

Review 6.  Targeted α-particle therapy of bone metastases in prostate cancer.

Authors:  Hossein Jadvar; David I Quinn
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

7.  α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.

Authors:  Sofia H L Frost; Brian W Miller; Tom A Bäck; Erlinda B Santos; Donald K Hamlin; Sue E Knoblaugh; Shani L Frayo; Aimee L Kenoyer; Rainer Storb; Oliver W Press; D Scott Wilbur; John M Pagel; Brenda M Sandmaier
Journal:  J Nucl Med       Date:  2015-09-03       Impact factor: 10.057

8.  (S)-5-(p-nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics.

Authors:  Gyula Tircsó; Eniko Tircsóné Benyó; Eul Hyun Suh; Paul Jurek; Garry E Kiefer; A Dean Sherry; Zoltán Kovács
Journal:  Bioconjug Chem       Date:  2009-03-18       Impact factor: 4.774

Review 9.  Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.

Authors:  Shagufta Shaheen; Farshad Moradi; Gerardo Gamino; Pamela L Kunz
Journal:  Curr Treat Options Oncol       Date:  2020-03-14

10.  Analysis of the contribution of charge transport in iodine-125-induced DNA damage.

Authors:  Thabisile Ndlebe; Igor Panyutin; Ronald Neumann
Journal:  Radiat Res       Date:  2010-01       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.